Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 7, 2025
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing
Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program
Read more at globenewswire.comNASDAQ:DSGN (9/11/2025, 12:13:03 PM)
6.095
-0.04 (-0.57%)
Find more stocks in the Stock Screener
